References
- Pischik E, Kauppinen R. An update of clinical management of acute intermittent porphyria. Appl Clin Genet. 2015;8:201–214.
- Sardh E, Harper P, Balwani M, et al. Phase 1 trial of an RNA interference therapy for acute intermittent porphyria. N Engl J Med. 2019;380(6):549–558.
- Chen B, Solis-Villa C, Hakenberg J, et al. Acute intermittent porphyria: predicted pathogenicity of HMBS variants indicates extremely low penetrance of the autosomal dominant disease. Hum Mutat. 2016;37(11):1215–1222.
- Nordmann Y, Puy H, Da Silva V, et al. Acute intermittent porphyria: prevalence of mutations in the porphobilinogen deaminase gene in blood donors in France. J Intern Med. 1997;242(3):213–217.
- Ramanujam V-M, Anderson KE. Porphyria diagnostics-part 1: a brief overview of the porphyrias. Curr Protocol Hum Genet. 2015;86(1):17.20.1–17.20.26.
- Simon A, Pompilus F, Querbes W, et al. Patient perspective on acute intermittent porphyria with frequent attacks: a disease with intermittent and chronic manifestations. Patient. 2018;11(5):527–537.
- Neeleman RA, Wagenmakers MA, Koole Lesuis RH, et al. Medical and financial burden of acute intermittent porphyria. J Inherit Metab Dis. 2018;41(5):809–817.
- Yarra P, Faust D, Bennett M, et al. Benefits of prophylactic heme therapy in severe acute intermittent porphyria. Mol Genet Metab Rep. 2019;19:100450.
- Rudnick SR, Pedro H, Merkel M, et al. The patient odyssey to confirmed acute hepatic porphyria diagnosis: clinical characteristics and healthcare utilization of patients preceding diagnosis of acute hepatic porphyria. Program no. P1459. ACG 2018 Annual Scientific Meeting Abstracts; 2018; Philadelphia, PA.
- Kollipara VN, Su J, Smalligan RD, et al. Abdominal pain and quadriparesis: acute intermittent porphyria at its worst. Abstracts from the 36th annual meeting of the society of general internal medicine; 2013; Denver, CO.
- Bonkovsky HL, Maddukuri VC, Yazici C, et al. Acute porphyrias in the USA: features of 108 subjects from porphyrias consortium. Am J Med. 2014;127(12):1233–1241.
- Pischik E, Kauppinen R. Neurological manifestations of acute intermittent porphyria. Cell Mol Biol (Noisy-le-Grand)). 2009;55(1):72–83.
- Anderson KE, Bloomer JR, Bonkovsky HL, et al. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med. 2005;142(6):439–450.
- D’Avola D, Lopez-Franco E, Sangro B, et al. Phase i open label liver-directed gene therapy clinical trial for acute intermittent porphyria. J Hepatol. 2016;65(4):776–783.
- Soonawalla ZF, Orug T, Badminton MN, et al. Liver transplantation as a cure for acute intermittent porphyria. Lancet. 2004;363(9410):705–706.
- Dowman JK, Gunson BK, Mirza DF, et al. Liver transplantation for acute intermittent porphyria is complicated by a high rate of hepatic artery thrombosis. Liver Transpl. 2012;18(2):195–200.
- Panhematin (R) (hemin for injection) [prescribing information]. Lebanon, NJ: Recordati Rare Diseases, Inc; 2017.
- Givlaari (R) (givosiran) [prescribing information]. Cambridge, MA: Alnylam Pharmaceuticals, Inc; 2019.
- Marsden JT, Guppy S, Stein P, et al. Audit of the use of regular haem arginate infusions in patients with acute porphyria to prevent recurrent symptoms. JIMD Rep. 2015;22:57–65.
- Gouya L, Bloomer JR, Balwani M, et al. An analysis of healthcare utilization and costs associated with patients with acute hepatic porphyrias (ahps) with recurrent attacks in explore: a prospective, multinational natural history study of patients with ahp. Value Health. 2018;21:S125.
- Nguyen MH, Burak Ozbay A, Liou I, et al. Healthcare resource utilization and costs by disease severity in an insured national sample of us patients with chronic hepatitis b. J Hepatol. 2019;70(1):24–32.
- Agarwal S, McManus A, Querbes W, et al. Developing an algorithm to identify patients with acute intermittent porphyria in an administrative claims database. Value Health. 2018;21:S213.
- Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
- Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in icd-9-cm and icd-10 administrative data. Med Care. 2005;43(11):1130–1139.
- U.S. Bureau of Labor Statistics. Consumer price index for all urban consumers: medical care [cpimedsl]. FRED, Federal Reserve Bank of St Louis; 2019. Available from: https://fredstlouisfedorg/series/CPIMEDSL.
- Sheridan K. FDA approves Alnylam’s Givlaari, second-ever drug based on RNAi. Boston (MA): STAT; 2019.